Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials.
Kazumasa SaigohTakao TakeshimaMasami NakaiYoshiyuki ShibasakiMiki IshidaXiaoping NingSteve BarashYuki IsogaiNobuyuki KogaPublished in: Journal of pain research (2023)
Despite the limitations of subgroup analyses, these consistent results confirm the efficacy and tolerability of fremanezumab in Japanese patients with CM.